Real-time polymerase chain reaction, usually called qPCR, detects and tracks a selected DNA target while amplification is happening. Fluorescent signals rise as the target is copied, allowing the laboratory to determine whether a sequence is present and, in many assays, estimate how much was in the original sample. When the starting material is RNA, a reverse-transcription step converts it to complementary DNA before qPCR; this combined method is written RT-qPCR.
Clinical qPCR is used for viral-load testing, rapid pathogen detection, known genetic variants, cancer biomarkers, gene-fusion monitoring, copy-number measurement, and selected gene-expression assays. The result may be qualitative, quantitative, or semiquantitative. A cycle threshold value by itself is not a universal measure of disease severity or infectiousness because specimen type, collection quality, target gene, reagents, instrument, and reporting rules all affect it. Reliable interpretation starts with the exact assay and its validated purpose, not with a single number taken out of context.
- qPCR detects a specific target and measures fluorescence during amplification, producing faster and more informative results than end-point PCR for many uses.
- A lower Cq or Ct usually reflects more starting target, but values should not be compared across different assays or laboratories without validated calibration.
- A detected viral target does not always prove active or contagious infection, especially when nucleic acid can persist after recovery.
- A negative qPCR result does not exclude disease when collection timing, specimen quality, inhibition, or low target levels reduce sensitivity.
- Quantitative results must use the reported units and reference method, such as IU/mL, copies/mL, log units, percentage, or normalized expression.
Table of Contents
- How Real-Time PCR Generates a Signal
- Qualitative, Quantitative, and Relative Assays
- Where qPCR Is Used in Clinical Care
- Reading Ct, Cq, and Viral-Load Results
- Genetic Variant and Cancer Results
- Controls, Calibration, and Analytical Quality
- False-Positive, False-Negative, and Borderline Results
- Sample Preparation, Timing, and Next Steps
How Real-Time PCR Generates a Signal
qPCR uses the same basic copying cycle as conventional PCR: DNA strands separate, primers bind to the target, and a heat-stable polymerase extends the new strands. The difference is that the instrument measures fluorescence during every cycle. The rising signal shows when amplification becomes distinguishable from background noise.
The reaction generally includes template DNA, forward and reverse primers, nucleotides, magnesium, buffer, polymerase, and a fluorescent detection system. If the original sample contains RNA, reverse transcriptase first makes complementary DNA. RNA quality and reverse-transcription efficiency then become additional sources of variation.
Two common fluorescence strategies are used:
- DNA-binding dyes fluoresce more strongly when bound to double-stranded DNA. They are flexible and relatively inexpensive, but they can also detect nonspecific products. Melt-curve analysis helps determine whether the expected product predominates.
- Sequence-specific probes bind within the amplified region and emit a signal only when the intended target is copied. Probe assays generally provide greater specificity and support multiplexing, in which different fluorescent labels identify several targets in the same reaction.
During early cycles, fluorescence remains below the measurable background. As product accumulates, the signal enters an exponential phase. The instrument assigns a quantification cycle, commonly called Cq. Many reports and platforms use Ct, or cycle threshold, for a similar concept. Lower Cq values usually indicate that the reaction crossed the threshold sooner because more target was present at the start.
The number is not an exact molecule count unless the assay is calibrated for quantification. Even in a quantitative test, extraction volume, sample input, reaction efficiency, and the standard material determine the reported concentration. A qPCR instrument does not directly “see viral load” or “measure gene activity”; it measures fluorescence and uses a validated model to translate that signal into a clinical result.
Amplification efficiency describes how much product increases in each cycle. An ideal reaction doubles the target, corresponding to 100% efficiency, but real assays operate within an accepted range. Poor primer design, inhibitors, damaged nucleic acid, or competing targets can reduce efficiency. Very high apparent efficiency may signal nonspecific amplification, pipetting problems, or an unsuitable standard curve.
Real-time detection reduces the need to open tubes after amplification, lowering carryover-contamination risk. It also shortens turnaround and creates more quantitative information than simply viewing a final band on a gel. These advantages have made qPCR a core method within the broader family of PCR tests.
Qualitative, Quantitative, and Relative Assays
Not every qPCR test is truly quantitative. The intended reporting model determines what can be concluded.
Qualitative detection
A qualitative assay reports detected, not detected, presumptive positive, inconclusive, or invalid. Fluorescence and cycle values are used internally, but the test is validated to answer whether the target is present above a threshold. Many respiratory, gastrointestinal, sexually transmitted infection, and inherited-variant assays use this format.
A detected result does not mean the amount has been measured accurately. Some qualitative assays suppress Cq values because those numbers have not been validated for patient-to-patient comparisons or treatment decisions.
Absolute quantification
Absolute qPCR compares the patient sample with standards containing known target amounts. A standard curve relates Cq to concentration. The final result may be reported as copies/mL, international units per milliliter, copies per reaction, or another calibrated unit.
International units improve comparability when a recognized reference standard exists, but different assays can still show systematic differences. Serial viral-load monitoring is usually most interpretable when performed with the same assay, specimen type, and laboratory.
The limit of detection is the lowest level the assay can detect reliably. The lower limit of quantification is the lowest level it can measure with acceptable precision and accuracy. A target may therefore be “detected below the quantifiable range.” This is not the same as a precise low number or a fully negative result.
Relative quantification
Relative qPCR compares expression of a target gene with one or more reference genes and with a calibrator sample. Results may be expressed as fold change using a delta-delta Cq approach. The calculation assumes that target and reference reactions have suitable and similar efficiencies.
Reference genes are sometimes called housekeeping genes, but their expression is not automatically stable in every tissue, disease, or treatment. Valid assays select and verify reference targets for the specific specimen and clinical purpose.
Semiquantitative reporting
Some assays group signals into categories such as low, medium, or high; report a percentage relative to a control gene; or use Cq ranges as part of an interpretive algorithm. These results are meaningful only within that validated system. A “high positive” on one platform cannot be converted reliably into a viral load or allele fraction from another.
Digital PCR uses partition counting rather than a continuous standard curve and may offer more precise low-level quantification in selected settings. It is related to qPCR but is a separate methodology with its own validation and reporting requirements.
Where qPCR Is Used in Clinical Care
qPCR can be adapted to any question that can be represented by a specific nucleic-acid target and validated specimen.
Viral and other infectious-disease testing
Real-time PCR detects viral DNA directly or viral RNA after reverse transcription. It is used for acute diagnosis, screening, and quantitative monitoring. Examples include respiratory viruses, hepatitis viruses, HIV, cytomegalovirus, Epstein-Barr virus, BK virus, and herpesviruses. Bacterial, fungal, and parasitic targets can also be detected.
A qualitative assay may identify an organism rapidly, while quantitative viral-load testing supports treatment monitoring, transplant care, or risk assessment. The correct specimen is essential. A blood viral load and a swab-based detection test answer different questions and may use different units and cutoffs.
Multiplex qPCR panels can test many organisms at once. They improve speed and sample efficiency, but a positive target may represent colonization, prolonged shedding, or a coinfection that does not explain the symptoms. Clinical interpretation may still require culture, antigen testing, microscopy, serology, or imaging.
Inherited variants and genotyping
Allele-specific probes can distinguish a known nucleotide change from the usual sequence. A targeted assay may identify a familial pathogenic variant, a common pharmacogenetic allele, or a disease-associated genotype. Results often appear as variant detected/not detected, heterozygous, homozygous, or no-call.
This method is efficient when the exact variant is known. It is not a comprehensive search of the gene. A negative targeted qPCR result excludes only the tested change within the assay’s validated performance. Full sequencing or a broader genetic variant test may be needed when many possible variants can cause the condition.
Copy-number qPCR compares amplification of a target region with a reference region. It can detect selected deletions or duplications, but single-exon changes, mosaic copy number, pseudogenes, and variable sample quality can complicate interpretation. Laboratories often confirm important findings with another method.
Cancer diagnosis and monitoring
qPCR can detect recurrent tumor variants or fusion transcripts. It is particularly useful when a cancer has a well-defined molecular target that can be measured over time. In some leukemias, standardized RT-qPCR monitors disease-associated fusion transcripts and expresses the result on a defined scale or as a ratio to a control gene.
A falling molecular marker can support treatment response; a rising marker may suggest molecular relapse or resistance. The meaning depends on the disease-specific protocol, sampling schedule, treatment stage, and magnitude of change. A single small increase may reflect analytic variation and often requires confirmation.
Tumor tissue qPCR can detect hotspot mutations that guide therapy. Plasma qPCR or digital PCR may identify circulating tumor DNA, but a negative blood result can occur when the tumor sheds little DNA. Tissue testing may still be needed.
Gene expression and transplant monitoring
RT-qPCR measures selected RNA transcripts in tumors, immune cells, or other tissues. Some multigene expression tests use qPCR-generated values within a proprietary score. The final score may estimate recurrence risk or support treatment decisions, but it should not be interpreted as a direct measurement of one gene alone.
After transplantation, qPCR can monitor viruses, donor-derived targets, or disease-specific molecular markers. Trends are often more informative than an isolated value, particularly when the same method and specimen conditions are maintained.
Reading Ct, Cq, and Viral-Load Results
Cq and Ct are technical values, not diagnoses. A result should first be read according to the laboratory’s final interpretation.
| Report term | Usual meaning | Important caution |
|---|---|---|
| Detected or positive | Target signal met the assay’s criteria | Does not necessarily prove active disease, viability, or severity |
| Not detected or negative | No reportable target signal was found | Does not exclude target below the limit or in a poorly collected sample |
| Detected, below quantification | Target is likely present, but too low for reliable numerical measurement | Do not treat the lower reporting limit as the patient’s exact value |
| Invalid | Control failure or unacceptable reaction | Usually requires repeat extraction or recollection |
| Inconclusive or indeterminate | Borderline, partial, or inconsistent signal | Follow the assay-specific repeat-testing guidance |
A difference of one Cq represents about a twofold target difference only when amplification is near ideal. A difference of approximately 3.3 cycles corresponds roughly to a tenfold difference. These rules are approximations and should not replace the test’s calibration curve.
For viral load, look for the units and whether the result is linear or logarithmic. A change from 10,000 to 100,000 copies/mL is a tenfold increase, equal to 1 log10. A shift from 3.0 to 4.0 log10 is also tenfold. Laboratories may define the smallest change considered clinically meaningful because every assay has measurement variation.
High Cq values occur late in amplification and often represent low target amounts. Near the detection limit, repeat reactions may not agree because only a few target molecules are distributed among aliquots. Late signals can also arise from nonspecific products or contamination. The laboratory’s rules determine whether such a signal is positive, inconclusive, or negative.
Cq cannot be used as a universal measure of contagiousness. Collection technique can change the amount of material on a swab, and different assays target different genes with different efficiencies. Time since symptom onset, immune status, specimen site, and whether detected nucleic acid comes from viable virus also matter. Culture or clinical evidence may not align perfectly with qPCR.
Serial monitoring requires consistent conditions. Changing laboratories or assay platforms can create an apparent jump or drop unrelated to biology. When a method change is unavoidable, the clinician may establish a new baseline or interpret overlapping measurements cautiously.
Genetic Variant and Cancer Results
A qPCR genotyping report may list two alleles, a variant status, or a copy-number estimate. Interpretation depends on what the assay targets.
For a known germline variant:
- Variant not detected means the specific change was not found above the assay threshold. It does not exclude other disease-causing variants.
- Heterozygous generally means one tested chromosome copy carries the variant and the other does not.
- Homozygous generally means both tested copies carry the variant, although rare technical issues such as allele dropout or copy-number changes can complicate the pattern.
- No-call or indeterminate means the assay could not assign a genotype reliably.
Whether a genotype causes disease depends on inheritance, penetrance, gene function, and variant classification. A qPCR result may correctly identify a nucleotide but cannot by itself establish that the variant is pathogenic. The report should connect the genotype with current clinical evidence.
In tumor testing, the target may be an acquired mutation. “Detected” can support eligibility for a targeted therapy or define a disease subgroup. The assay may report an allele fraction or only a qualitative result. Tumor purity, normal-cell admixture, copy-number changes, and subclonal populations affect the signal.
For minimal residual disease, the test often follows a marker established at diagnosis. Results may be expressed as a normalized ratio, percent, log reduction, or detected/not detected at a stated sensitivity. Molecular remission means the marker is below a defined threshold; it does not guarantee that every malignant cell is absent. A result also cannot be interpreted without knowing whether the original tumor carried the marker and whether the sample contained enough suitable cells or RNA.
A rising cancer marker is not always immediate proof of relapse. Small fluctuations near the limit can occur. Disease-specific guidelines may require confirmation in a new sample, a particular log increase, or correlation with blood counts, bone marrow findings, imaging, and symptoms.
Targeted qPCR is often faster and more sensitive for one known marker than broad sequencing. Sequencing is more useful when the relevant variant is unknown or many genes must be assessed. The two methods are frequently used together: sequencing discovers a marker, and qPCR tracks it efficiently over time.
Controls, Calibration, and Analytical Quality
A credible qPCR result depends on controls that distinguish a true negative from a failed reaction and a true positive from contamination.
A no-template control contains reaction reagents without patient nucleic acid. Amplification can signal contamination or nonspecific product. A positive control confirms that reagents and cycling conditions can detect the target. An internal amplification control travels with the patient sample and checks extraction, sample adequacy, and inhibition. A negative extraction control can reveal contamination introduced during extraction.
For RNA assays, a no-reverse-transcriptase control may show whether genomic DNA is contributing to the signal. Reference genes help normalize input and RNA quality, but they must be stable in the sample type. Multiple reference genes can improve reliability for expression studies.
Quantitative assays require calibrators or standards. A standard curve should cover the reportable range and show acceptable slope, efficiency, linearity, and replicate agreement. Reference materials should resemble patient samples as closely as practical. Synthetic targets can verify sequence detection but may not fully test extraction from real tissue or blood.
The laboratory validates:
- accuracy and precision;
- analytical sensitivity and specificity;
- limit of blank, detection, and quantification when applicable;
- linear range;
- interference and inhibition;
- carryover contamination;
- specimen stability;
- multiplex performance;
- robustness across reagent lots, operators, and instruments.
The 2025 MIQE 2.0 recommendations emphasize transparent reporting of sample handling, nucleic-acid quality, assay design, validation, controls, analysis, and data interpretation. Although MIQE was developed for reliable qPCR practice and publication, the same principles explain why two superficially similar qPCR results may not be interchangeable.
Clinical laboratories also use proficiency testing, quality-control trends, instrument maintenance, and predefined acceptance rules. A run can be rejected even when a patient target appears positive if required controls fail.
False-Positive, False-Negative, and Borderline Results
False-positive qPCR results can arise from contamination with amplified product, positive-control material, another specimen, or environmental target DNA. Probe cross-reactivity, nonspecific dye signal, sample mix-up, and threshold-setting errors are other causes. Closed-tube detection lowers contamination risk but cannot prevent errors during collection, extraction, or reagent preparation.
A biologically real target can also be clinically misleading. Viral nucleic acid may remain after symptoms resolve. A resistance gene may be present in an organism that is not causing disease. A low-level tumor variant can reflect clonal hematopoiesis rather than the solid tumor being evaluated. These are not necessarily analytical false positives, but they can lead to incorrect conclusions without context.
False-negative results may result from:
- collection from the wrong site or at the wrong time;
- low target burden or intermittent shedding;
- degraded DNA or RNA;
- inhibitors such as heme, mucus, complex medications, or specimen additives;
- mutations under a primer or probe;
- poor reverse transcription;
- insufficient tumor cells;
- target level below the validated limit;
- a disease-causing variant not included in the assay.
Borderline results deserve careful handling. Repeating the same extract can test reaction reproducibility, but recollecting a specimen may better address poor collection or biological timing. A different target or method may clarify primer-site variation or nonspecific amplification.
An invalid result should not be converted into a negative. If the internal control fails, the laboratory may dilute the extract to reduce inhibition, repeat extraction, or request a new sample. Dilution can reduce inhibitors but also lowers the target concentration, so the strategy must be validated.
Clinical urgency affects the next step. A severely ill patient with a strong suspicion of infection may need treatment and additional testing while a negative qPCR is investigated. A low-level molecular cancer marker may be repeated according to the disease protocol rather than acted on from one measurement.
Sample Preparation, Timing, and Next Steps
Most blood-based genetic or viral-load qPCR tests do not require fasting. Do not stop medications unless the ordering clinician gives specific instructions. Preparation focuses on obtaining the right specimen under the right conditions.
For swabs, follow instructions about site, depth, rotation, and transport medium. Eating, drinking, mouthwash, topical medication, recent urination, or sexual activity may affect particular oral or genital specimens. For blood tests, collection tube type and prompt processing can matter, especially for RNA. Tumor tissue must contain enough viable tumor and may require pathology selection.
Provide previous results when monitoring a trend. The laboratory name, platform, units, and date help determine whether values are directly comparable. For a familial genetic variant, provide the relative’s complete report so the exact gene, transcript, and nucleotide change are tested.
Turnaround may be less than an hour for some near-patient cartridges, several hours to days for routine infectious assays, and several days to two weeks for specialized genetic, oncology, or send-out testing. Quantitative runs may be batched, and unexpected results may need repeats or confirmation.
After receiving the report:
- Read the final interpretation before focusing on Cq.
- Confirm the specimen type, target, units, and reference range.
- Check whether the result is qualitative, quantitative, or below quantification.
- Compare serial results only when the methods are compatible.
- Ask whether an unexpected or borderline result needs repeat sampling.
- For genetic findings, ask whether broader testing or genetic counseling is appropriate.
- For cancer findings, review the result with the oncology team in the disease-specific context.
qPCR is exceptionally useful when a clearly defined target must be detected quickly or measured repeatedly. Its precision does not remove the need for clinical judgment. The fluorescence curve becomes meaningful only after the assay’s controls, validation, specimen, and medical question are considered together.
References
- MIQE 2.0: Revision of the Minimum Information for Publication of Quantitative Real-Time PCR Experiments Guidelines 2025 (Guideline)
- Development and validation of qPCR methods for nucleic acid biomarkers 2023 (Review)
- Recommendations on qPCR/ddPCR assay validation by GCC 2022 (Position Statement)
- Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in the UK and Ireland: a multicentre audit 2022 (Review)
- Real-Time PCR: Current Techniques, Applications, and Role in COVID-19 Diagnosis 2022 (Review)
- Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method 2001 (Methods Paper)
Disclaimer
qPCR results must be interpreted using the specific assay, specimen, controls, units, timing, and clinical situation. Do not use a Ct or Cq value alone to judge infectiousness, treatment response, inherited risk, or cancer status. Seek prompt medical evaluation when symptoms are severe or when a result conflicts with a clinician’s concern.
